A new study published in the American Journal of Obstetrics and Gynecology highlights a potential link between Zofran—an anti-nausea medication sometimes prescribed for morning sickness—and an increased risk of severe birth defects. Doctor Gideon Koren’s study, published in the December 2014 issue, emphasizes that physicians cannot rule out the risk of harming a fetus when the drug is taken during pregnancy.
The study involved more than 900,000 Danish women, and found that children born to women who used Zofran to combat morning sickness were twice as likely to suffer from cardiac malformations. The study found an overall 30% increase in likeliness of congenital malformations among babies born to women who took Zofran during pregnancy.
Zofran was originally approved by the U.S. Food and Drug Administration to combat nausea in patients who are undergoing cancer therapy. However, some physicians have prescribed Zofran to combat morning sickness in pregnant women, a condition which the FDA did not approve the drug to treat.